← Leaderboards
Robbie G. Majzner
Children'S Hosp Of Philadelphia
$6,350,674
Attributed
$7,995,109
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,995,109 · 5
By mechanism
DP2$2,484,600 · 1
U01$2,317,710 · 1
OT2$1,705,825 · 1
P01$758,604 · 1
R61$728,370 · 1
Top collaborators
- Kimberly Stegmaier3 shared
- Ido Amit1 shared
- Jonathan Kipnis1 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- John M Maris$30,818,378
- Shahab Asgharzadeh$4,442,796
- Crystal Mackall$19,988,621
- Jessica B Foster$905,375
- Laurie Lenox$126,269
Others in their field
Other Emerging Leaders on “T-Lymphocyte”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Crystal Mackall · Children'S Hosp Of Philadelphia$16,367,876
- Wilton B Williams · Duke University$16,226,847
- Gary Fanger · Rise Therapeutics, Llc$15,372,982
- Aaron Esser-Kahn · University Of Chicago$13,378,548
Research focus
T-LymphocyteResponseMalignant NeoplasmsChimeric Antigen Receptor T CellsChimeric Antigen ReceptorImmunotherapeutic AgentTumorNeoplastic CellAntigensRelapseSurfaceImmunotherapySignal TransductionIn VitroRegulationEngineeringCellsMouse ModelLinkIn VivoTissuesCaringChildhood Solid NeoplasmInhibitor
Grant awards (12)
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma$767,167
U01 · FY2025 · CA · contact PI
Engineered T cell approaches for Alzheimer's disease$728,370
R61 · FY2025 · AG
NexTGen - DFCI$573,955
OT2 · FY2025 · CA · contact PI
Leveraging biological insights to enhance immunotherapies$407,870
P01 · FY2025 · CA · contact PI
Hijacking the T cell machinery for logic-gated CAR T cell control$1,068,000
DP2 · FY2024 · CA · contact PI
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma$755,393
U01 · FY2024 · CA · contact PI
Leveraging biological insights to enhance immunotherapies$350,734
P01 · FY2024 · CA · contact PI
NexTGen - DFCI$215,376
OT2 · FY2024 · CA · contact PI
NexTGen - DFCI$916,494
OT2 · FY2023 · CA · contact PI
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma$795,150
U01 · FY2023 · CA · contact PI
Hijacking the T cell machinery for logic-gated CAR T cell control$800,041
DP2 · FY2021 · CA · contact PI
Hijacking the T cell machinery for logic-gated CAR T cell control$616,559
DP2 · FY2021 · CA · contact PI